Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $13.475 million which beat the analyst consensus estimate of $13.199 million by 2.09 percent. This is a 0.12 percent increase over sales of $13.459 million the same period last year.